



Affordable production of pathogen

inactivated platelet concentrates

Karolinska University Hospital in Stockholm, Sweden, produces about 9,000 units of buffy coat derived platelets (BCPs) per year for patient use. Until 2014, BCPs were produced using the OrbiSac System together with the enhanced Bacterial Detection System (eBDS™) as a blood safety measure. To further improve blood safety, pathogen inactivation (PI) was considered. However, the challenge was to implement PI without increasing the costs. A feasible solution was a combination of the INTERCEPT™ Blood System and manual production of double dose buffy coat derived platelets (DD-BCPs).



Global Headquarters

Cerus Corporation
2550 Stanwell Drive
Concord, CA 94520, USA
+1 925 288 6000

European Headquarters

Cerus Europe B.V.
Stationsstraat 79-D
3811 MH Amersfoort
The Netherlands
+31 33 496 0600

customer_services@cerus.com
www.interceptbloodsystem.com
www.cerus.com

Use of INTERCEPT plasma or platelets is contraindicated in patients with a history of allergic response to amotosalen or psoralens. Consult instructions for use for indications, contraindications, warnings and precautions.